About This Product

This research peptide blend combines two of the most extensively studied compounds within the growth hormone secretagogue (GHS) category: CJC-1295, a synthetic analog of Growth Hormone Releasing Hormone <>(GHRH), and Ipamorelin, a selective Growth Hormone Releasing Peptide (GHRP). CJC-1295 CJC-1295 is a tetrasubstituted GHRH analog developed to enhance the biological half-life and stability of native GHRH. In experimental models, it has been observed to: • Prolong the duration of GH-releasing activity via binding to GHRH receptors • Increase GH pulse amplitude without significantly affecting frequency • Demonstrate potential for reduced degradation through binding to albumin (DAC-modified variant) • Allow for less frequent administration in research applications due to extended plasma half-life Ipamorelin Ipamorelin is a pentapeptide GHRP that selectively binds to the ghrelin receptor (GHS-R1a). It has been widely studied for: • Stimulating GH release in a dose-dependent manner in lab models • Displaying minimal activity on cortisol, prolactin, or aldosterone levels, suggesting a more selective profile • Working independently of GHRH pathways, often examined for additive effects when paired with GHRH analogs The Blend The CJC-1295 / Ipamorelin blend combines two peptides from distinct but complementary families, one targeting the GHRH receptor (CJC-1295) and the other engaging the ghrelin receptor (Ipamorelin). This dual-receptor approach enables researchers to investigate the coordinated activity of two independent signaling pathways involved in growth hormone regulation. The interaction between these pathways has made this combination a frequent subject of interest in endocrine and metabolic research models.